Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
BEAM Stock Chart & Stats
$28.46
-$0.69(-2.55%)
At close: 4:00 PM EST
$28.46
-$0.69(-2.55%)
Day’s Range― - ―
52-Week Range$13.53 - $36.44
Previous CloseN/A
Volume491.48K
Average Volume (3M)1.65M
Market Cap
$2.90B
Enterprise Value$2.89B
Total Cash (Recent Filing)$1.25B
Total Debt (Recent Filing)$293.88M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
May 12, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.33
Shares Outstanding101,856,250
10 Day Avg. Volume1,642,582
30 Day Avg. Volume1,646,199
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue20.66
Enterprise Value/Gross Profit-16.38
Enterprise Value/Ebitda-38.53
Forecast
1Y Price Target
$48.75Price Target Upside71.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-4.32
Revenue Forecast (FY)$41.03M
Bulls Say, Bears Say
Bulls Say
FinancingNondilutive financing from a specialty partner extends the company's development runway and lowers the likelihood of immediate equity dilution, supporting continued program advancement.
Regulatory PathwayRegulatory alignment on a potential accelerated approval pathway for the alpha-1 antitrypsin program could enable approval based on biomarker data and shorten the time to market.
Strategic PartnershipExercise of an exclusive license by a major pharmaceutical partner validates the company's liver delivery technology and creates potential milestone and profit-sharing revenue upside.
Bears Say
Clinical Development RiskStandard biotech risks such as trial failures and regulatory setbacks could delay or halt program progress and materially affect the company's outlook.
Commercial AdoptionReliance on an ex vivo transplantation procedure may hinder patient and provider uptake relative to in vivo approaches, potentially limiting commercial penetration even if therapies are approved.
Financial SustainabilityConsensus estimates reflecting ongoing losses indicate the company remains unprofitable on traditional measures, raising the prospect of additional funding needs if development continues.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $13.53 and its highest was $36.44 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $2.90B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 71 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Feb 24, 2026. The company reported $2.33 earnings per share for the quarter, beating the consensus estimate of -$1.01 by $3.34.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics dividends here
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 101,856,250 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of $2.33 in its last earnings report, beating expectations of -$1.01. Following the earnings report the stock price went up 13.978%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Currently, no hedge funds are holding shares in BEAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beam Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.75 (71.29% Upside)
$48.75 (71.29% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.97%
12-Months-Change
Fundamentals
Return on Equity
-8.11%
Trailing 12-Months
Asset Growth
34.19%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
BEAM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial positive momentum: a new liver-targeted PKU program with strong preclinical efficacy, constructive FDA engagement around an umbrella platform approach, demonstrated LNP and manufacturing capabilities, and a major non-dilutive financing that extends runway into mid-2029. Key risks highlighted include regulatory ambiguity for novel individualized pathways, the large diversity of PAH variants (necessitating personalized approaches), limited public detail on bystander/off-target profiles, and conditional milestone-based financing. On balance, the updates emphasize progress, resources, and clear near-term milestones while acknowledging technical and regulatory uncertainties that are typical for platform-based gene editing development.View all BEAM earnings summariesBEAM Stock 12 Month Forecast
Average Price Target
$48.75
▲(71.29% Upside)
Technical Analysis
Denali Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---